Welcome!

News Feed Item

Pressure BioSciences, Inc. Reports Strong Fourth Quarter and Fiscal Year 2013 Financial Results

Total Revenue Up 64% (Q/Q) and 21% (Y/Y)

SOUTH EASTON, Mass., April 1, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three-month period and fiscal year ended December 31, 2013 and provided a business update.

Total revenue for the fourth quarter of 2013 was $354,052 compared to $216,032 for the same period in 2012, a 64% increase. Revenue from the sale of products and services was $300,628 for Q4 2013 compared to $122,285 for the same period in 2012, a 146% increase.  Grant revenue in Q4 2013 was $53,424 compared to $93,747 for the same period in the prior year.  Sales of consumables were $52,968 for the three months ended December 31, 2013 compared to $18,624 for the same period in 2012, an increase of 184%.

Operating loss for the fourth quarter of 2013 decreased to $900,110 from $1,129,750 for the same period in 2012, a reduction of 20%.  Contributing to this decrease in operating loss was a quarter over quarter decrease in general and administrative expenses of $268,105, or 30%.

Loss per common share (basic and diluted) was $0.16 for the 2013 fourth quarter compared to $0.10 for the same period in 2012.  The additional loss per common share was due primarily to the change in the fair value of the derivative instruments in Q4 2013.

Total revenue for the fiscal year 2013 was $1,503,288 compared to $1,238,217 for the fiscal year 2012, a 21% increase.  Revenue from the sale of products and services was $1,046,678 for FY 2013 compared to $809,308 for FY 2012, a 29% increase.  Grant revenue in FY 2013 was $456,610 compared to $428,909 for FY 2012.  Sales of consumables were approximately $157,676 for FY 2013 compared to approximately $85,493 for FY 2012, an increase of 84%.

Operating loss for the fiscal year 2013 decreased to $3,327,192 from $3,463,642 for the fiscal year 2012, a reduction of 4%.  Contributing to this decrease in operating loss were decreases in total operating expenses of $22,792 and increased gross margin of $113,658.

Loss per common share (basic and diluted) was $0.44 for 2013 compared to $0.43 for the same period in 2012. 

Richard P. Thomley, Chief Financial Officer of PBI, said: "In addition to strong quarter over quarter (Q4 2013 vs. Q4 2012) revenue increases, both total revenue and products and services revenue showed substantive sequential increases for the year (FY 2013 vs. FY 2012), posting gains of 21% and 29%, respectively. We achieved these results while also decreasing operating expenses. We believe that our financial performance for the fourth quarter and fiscal year 2013 reflect PBI's significant progress in our stated goal of developing a sound financial roadmap moving forward."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "During 2013, and the first three months of 2014, we achieved a number of notable financial and operational successes, including:

  • We closed the first three tranches ($2.8M) of our Series K PIPE (initial goal $1.5M)
  • We released our ultra-high pressure HUB880 instrument system to the market on time (Q1 2014)
  • We closed our $2.0M Series J PIPE, slightly over-subscribed at $2.04M
  • We reported increases in total revenue for Q1, Q2, Q3, and Q4 2013 vs. same quarters in 2012
  • We announced a Core Technology Breakthrough enabling our PCT Platform to develop integration with the dominant laboratory high-throughput robotic pipetting and automation footprint used worldwide
  • We reported on independent studies that showed our novel instrument systems could potentially (i) generate new insights into protein structure and function (for biomarker discovery and drug design); (ii) greatly accelerate rape kit testing; (iii) generate a new understanding of diseases and disorders related to the gastrointestinal tract through non-invasive means; and (iv) offer advantages in cancer, stem cell, and heart disease studies."  

Mr. Schumacher continued: "We believe that our product and services revenue will continue to increase in 2014 and beyond; that the distinct advantages of our pressure cycling-based products will continue to be reported by scientists worldwide; that the number of applications and thus fields of use for our products will continue to increase; and that we will be successful in continuing to raise the funds as required, to help us achieve our goal of financial self-sufficiency and profitability, with steadily increasing shareholder value as we move forward."

Earnings Call

The Company will hold an Earnings Conference Call at 4:15 PM EDT on Tuesday, April 1, 2014.  To attend this teleconference via telephone: Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International). Verbal Passcode (to be given to the operator: VS78313).  Conference ID:  880058.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.    

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward looking-statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter and fiscal year ended December 31, 2013 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com 
Please visit us on Facebook, LinkedIn, and Twitter.



Investor Contacts:


Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.

(508) 230-1828 (T)

Richard P. Thomley, Chief Financial Officer, Pressure BioSciences, Inc.

(508) 230-1828 (T)

Howard Gostfrand, President, American Capital Ventures

(858) 568-7059 (T)

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)






For the Three Months Ended





December 31,





2013


2012








Revenue:






Products, services, other


$300,628


$122,285


Grant revenue


53,424


93,747



Total revenue


354,052


216,032








Costs and expenses:






Cost of products and services


203,460


120,329


Research and development


248,284


189,988


Selling and marketing


179,114


144,057


General and administrative


623,304


891,409



Total operating costs and expenses


1,254,162


1,345,782










Operating loss


(900,110)


(1,129,750)








Other income (expense):






Interest expense, net


(109,642)


(62,350)


Other income (expense)


(320,292)


(36,322)


Change in fair value of derivative liabilities


(235,759)


144,840



Total other income (expense)


(665,693)


(46,168)









Loss before income taxes


(1,565,803)


(1,083,582)


Income tax benefit


-


2,014


Net loss


(1,565,803)


(1,081,568)


Accrued and deemed dividend on convertible preferred stock


(397,492)


(54,276)


Net loss applicable to common shareholders


$(1,963,295)


$(1,135,844)
















Net loss per share attributable to common stockholders - basic and

diluted

$(0.16)


$(0.10)









Weighted average common stock shares outstanding used in the

basic and diluted net loss per share calculation


11,955,789


11,804,368

 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

(AUDITED)






For the Year Ended





December 31,





2013


2012








Revenue:






Products, services, other


$1,046,678


$809,308


Grant revenue


456,610


428,909



Total revenue


1,503,288


1,238,217








Costs and expenses:






Cost of products and services


567,828


416,415


Research and development


1,035,426


965,623


Selling and marketing


752,288


714,635


General and administrative


2,474,938


2,605,186



Total operating costs and expenses


4,830,480


4,701,859










Operating loss


(3,327,192)


(3,463,642)








Other income (expense):






Interest expense, net


(339,818)


(133,417)


Other income (expense)


(531,130)


-


Change in fair value of derivative liabilities


113,713


144,840



Total other income (expense)


(757,235)


11,423









Loss before income taxes


(4,084,427)


(3,452,219)


Income tax benefit


-


2,014


Net loss


(4,084,427)


(3,450,205)


Accrued and deemed dividends on convertible preferred stock


(1,163,022)


(950,010)


Net loss applicable to common shareholders


$(5,247,449)


$(4,400,215)
















Net loss per share attributable to common stockholders - basic and

diluted

$(0.44)


$(0.43)









Weighted average common stock shares outstanding used in the

basic and diluted net loss per share calculation


11,821,870


10,154,175

 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(AUDITED)






December 31,


December 31,

ASSETS

2013


2012

CURRENT ASSETS





Cash and cash equivalents

$31,417


$1,461


Accounts receivable

147,635


216,265


Inventories, net of $50,000 reserve

736,676


923,362


Prepaid income taxes

7,381


7,381


Prepaid expenses and other current assets

85,573


83,435


      Total current assets

1,008,682


1,231,904

PROPERTY AND EQUIPMENT, NET

58,102


30,282


Deposits

-


6,472


Intangible assets, net

36.498


85,130

TOTAL ASSETS

$1,103,282


$1,353,788


LIABILITIES AND STOCKHOLDERS' DEFICIT




CURRENT LIABILITIES





Accounts payable

$1,102,772


$1,199,846


Accrued employee compensation

149,333


119,338


Accrued professional fees and other

615,244


267,936


Deferred revenue

28,189


46,466


Promissory note

75,000


75,000


Dividend liability

-


60,000


Related party debt

25,182


98,675


Convertible debt, net of debt discount of $331,806 at Dec. 31, 2013

 and $0 at Dec. 31, 2012

281,796


863,004


Other debt

89,989


-


Warrant derivative liability

344,570


160,812


Conversion option liability

356,197


-


      Total current liabilities

3,068,272


2,891,077

LONG TERM LIABILITIES





Deferred revenue

2,785


2,487

TOTAL LIABILITIES

3,071,057


2,893,564

STOCKHOLDERS' DEFICIT





Series D convertible preferred stock, $.01 par value; 850 shares authorized;

300 shares issued and outstanding on Dec. 31, 2013 and Dec. 31, 2012

3


3


Series G convertible preferred stock, $.01 par value; 240,000 shares authorized;

145,320 shares issued and outstanding on Dec. 31, 2013 and at Dec. 31, 2012

1,453


1,453


Series H convertible preferred stock, $.01 par value; 10,000 shares authorized

10,000 shares issued and outstanding on Dec. 31, 2013 and 0 at Dec. 31, 2012

100


-


Series J convertible preferred stock, $.01 par value; 6,250 shares authorized;

5,087.5 shares and 0 shares issued and outstanding on Dec. 31, 2013 and on

Dec. 31, 2012, respectively

51


-


Series K convertible preferred stock, $.01 par value; 15,000 shares authorized;

4,000 shares issued and outstanding on Dec. 31, 2013 and 0 at Dec. 31, 2012

40


-


Common stock, $.01 par value; 50,000,000 shares authorized;

 12,024,267 and 12,149,267 shares issued and outstanding on Dec. 31, 2013

and on Dec. 31, 2012, respectively

120,243


121,493


Warrants to acquire preferred stock and common stock

4,267,402


3,015,996


Additional paid-in capital

19,509,921


15,940,818


Accumulated deficit

(25,866,988)


(20,619,539)


      Total stockholders' deficit

(1,967,775)


(1,539,776)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$1,103,282


$1,353,788

 

SOURCE Pressure BioSciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band-aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It does...
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web ...